Published in Brain on March 12, 2007
Exome sequencing identifies FUS mutations as a cause of essential tremor. Am J Hum Genet (2012) 2.30
Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat Genet (2009) 2.29
Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor. Neurotoxicology (2007) 1.98
Essential tremors: a family of neurodegenerative disorders? Arch Neurol (2009) 1.49
LINGO1 rs9652490 is associated with essential tremor and Parkinson disease. Parkinsonism Relat Disord (2009) 1.18
LINGO1 variant increases risk of familial essential tremor. Neurology (2009) 1.16
Older onset essential tremor: More rapid progression and more degenerative pathology. Mov Disord (2009) 1.14
Environmental epidemiology of essential tremor. Neuroepidemiology (2008) 1.11
The role of FUS gene variants in neurodegenerative diseases. Nat Rev Neurol (2014) 1.04
Essential tremor as a neuropsychiatric disorder. J Neurol Sci (2009) 1.00
Tremor in 48,XXYY syndrome. Mov Disord (2009) 0.95
Population-based prospective study of cigarette smoking and risk of incident essential tremor. Neurology (2008) 0.92
Predicting age of onset in familial essential tremor: how much does age of onset run in families? Neuroepidemiology (2013) 0.91
Reappraisal of the role of the DRD3 gene in essential tremor. Parkinsonism Relat Disord (2008) 0.88
Blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor: repeat observation in cases and controls in New York. J Toxicol Environ Health A (2012) 0.88
The functional DRD3 Ser9Gly polymorphism (rs6280) is pleiotropic, affecting reward as well as movement. PLoS One (2013) 0.88
Key issues in essential tremor genetics research: Where are we now and how can we move forward? Tremor Other Hyperkinet Mov (N Y) (2013) 0.87
Overview of essential tremor. Neuropsychiatr Dis Treat (2010) 0.85
Evaluation of SCN8A as a candidate gene for autosomal dominant essential tremor. Parkinsonism Relat Disord (2008) 0.85
Histamine N-methyltransferase Thr105Ile is not associated with Parkinson's disease or essential tremor. Parkinsonism Relat Disord (2009) 0.84
DRD3 Ser9Gly and HS1BP3 Ala265Gly are not associated with Parkinson disease. Neurosci Lett (2009) 0.83
SLC1A2 variant is associated with essential tremor in Taiwanese population. PLoS One (2013) 0.82
What is essential tremor? Curr Neurol Neurosci Rep (2013) 0.79
Dopamine receptor D3 gene and essential tremor in large series of German, Danish and French patients. Eur J Hum Genet (2008) 0.79
Harmaline-induced tremor in mice: videotape documentation and open questions about the model. Tremor Other Hyperkinet Mov (N Y) (2013) 0.79
Genetic variants of α-synuclein are not associated with essential tremor. Mov Disord (2011) 0.78
Familial versus Sporadic Essential Tremor: What Patterns Can One Decipher in Age of Onset? Neuroepidemiology (2015) 0.77
LINGO1 variants in the French-Canadian population. PLoS One (2011) 0.77
Evaluating Familial Essential Tremor with Novel Genetic Approaches: Is it a Genotyping or Phenotyping Issue? Tremor Other Hyperkinet Mov (N Y) (2014) 0.76
Dystonia and Tremor: The Clinical Syndromes with Isolated Tremor. Tremor Other Hyperkinet Mov (N Y) (2016) 0.76
Beta-carboline alkaloids and essential tremor: exploring the environmental determinants of one of the most prevalent neurological diseases. ScientificWorldJournal (2010) 0.75
Tremor and Klinefelter's Syndrome. Tremor Other Hyperkinet Mov (N Y) (2015) 0.75
How to tackle tremor - systematic review of the literature and diagnostic work-up. Front Neurol (2012) 0.75
The prevalence of essential tremor in elderly Koreans. J Korean Med Sci (2014) 0.75
A GIPC1-Palmitate Switch Modulates Dopamine Drd3 Receptor Trafficking and Signaling. Mol Cell Biol (2016) 0.75
Autonomic dysfunction in patients with essential tremor. Neurol Sci (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Movement disorders in cerebrovascular disease. Lancet Neurol (2013) 2.81
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy (2011) 2.47
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord (2007) 2.34
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain (2008) 2.34
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Camptocormia: pathogenesis, classification, and response to therapy. Neurology (2005) 2.26
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord (2011) 2.16
Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg (2006) 2.02
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Update on blepharospasm: report from the BEBRF International Workshop. Neurology (2008) 1.87
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx (2006) 1.82
Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord (2006) 1.82
Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord (2010) 1.76
Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist (2008) 1.74
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci (2009) 1.73
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Premutation alleles associated with Parkinson disease and essential tremor. JAMA (2004) 1.65
Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun (2005) 1.64
Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci (2004) 1.62
Migraine headache in patients with Tourette syndrome. Arch Neurol (2003) 1.61
Minocycline in Huntington's disease: a pilot study. Mov Disord (2004) 1.59
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat (2010) 1.57
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord (2008) 1.56
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord (2005) 1.54
Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol (2005) 1.54
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol (2003) 1.53
Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord (2010) 1.52
Secondary tics and tourettism. Rev Bras Psiquiatr (2005) 1.47
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci (2011) 1.46
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis (2008) 1.43
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol (2005) 1.39
LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics (2010) 1.37
Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy (2008) 1.37
The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry (2013) 1.36
Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord (2003) 1.35
Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. J Neuropathol Exp Neurol (2004) 1.33
Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin (2004) 1.33
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord (2007) 1.32
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord (2010) 1.31
Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals (2011) 1.30
Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol (2006) 1.29
Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain (2006) 1.29
Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener (2013) 1.28
Redox control of the survival of healthy and diseased cells. Antioxid Redox Signal (2011) 1.27
Nurr1 in Parkinson's disease and related disorders. J Comp Neurol (2006) 1.27
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon (2013) 1.27
Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol (2002) 1.26
Runner's dystonia. J Neurol Sci (2006) 1.24
Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord (2004) 1.24
Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord (2006) 1.23
Iron dysregulation in movement disorders. Neurobiol Dis (2012) 1.22
miR-132 regulates the differentiation of dopamine neurons by directly targeting Nurr1 expression. J Cell Sci (2012) 1.21
Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. Neurobiol Aging (2007) 1.21
A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A (2006) 1.20
Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Curr Neuropharmacol (2013) 1.20
An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) (2013) 1.20
Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna) (2013) 1.20
Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord (2011) 1.18
Autophagy dysregulation in amyotrophic lateral sclerosis. Brain Pathol (2012) 1.18
Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord (2007) 1.18
Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology (2002) 1.18
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord (2007) 1.17
Reliability of a new scale for essential tremor. Mov Disord (2012) 1.17
Secondary paroxysmal dyskinesias. Mov Disord (2002) 1.17
Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord (2010) 1.17
Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother (2006) 1.16
Movement disorders in autoimmune diseases. Mov Disord (2012) 1.16